Physicians' Academy for Cardiovascular Education

Familial Hypercholesterolemia

Recently added learning

Statin therapy during pregnancy?

5' education - June 9, 2021 - Prof. Maciej Banach, PhD, MD

Huge advantage with ANGPTL3 inhibitor for HoFH patients with minimal to zero LDLR activity

3' education - Oct. 6, 2020 - Prof. Frederick Raal, MD

A novel small binding protein that targets PCSK9

3' education - Oct. 6, 2020 - Prof. Evan Stein, MD, PhD

Small interfering RNA against PCSK9 reduces LDL-c in HeFH independent of genotype

3' education - Oct. 6, 2020 - Prof. Frederick Raal, MD

Familial Hypercholesterolemia and Lp(a)

10' education - July 14, 2020 - Nick Nurmohamed, MD

Familial Hypercholesterolemia: Why and how to screen?

10' education - June 30, 2020 - Prof. Kees Hovingh, MD, PhD

Tools to detect FH

10' education - June 23, 2020 - Rens Reeskamp, MD

Familial hypercholesterolemia in children and adolescents

10' education - June 2, 2020 - Bert Wiegman, MD, PhD

One step closer to controlling LDL-c levels in HoFH with PCSK9i

3' education - Apr. 9, 2020 - Dirk Blom, PhD

Remarkable reduction of LDL-c with antibody against angiopoietin-like protein 3 in HoFH

3' education - Apr. 1, 2020 - Prof. Frederick Raal, PhD - ACC 2020

The mechanism of action of bempedoic acid

Feb. 2, 2020

New tool can help identify FH patients

3' education - Nov. 17, 2019 - Willem Bax, Alkmaar - AHA 2019, Philadelphia

What are the most important changes in the 2019 ESC/EAS Dyslipidemia Guidelines?

5' education - Oct. 23, 2019 - Paris, France - Prof. François Mach, MD

Prevalence and relevance of elevated Lp(a) in familial hypercholesterolemia

5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Prof. Børge Nordestgaard, MD

Efforts to move universal cholesterol screening before the age of 20 forward

3' education - May 29, 2019 - Maastricht, The Netherlands - Professor Kausik Ray, MD

Challenges for screening and treatment of FH patients in clinical cardiology

5' education - Feb. 13, 2019 - Kausik Ray, Kees Hovingh - Online CME

Identifying patients for PCSK9 therapy

10' education - Jan. 16, 2019 - Kees Hovingh, MD - Amsterdam, The Netherlands - Online CME

Novel PCSK9 outcomes in perspective: Lessons from FOURIER & ODYSSEY

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - Prof. Jennifer Robinson, MD - Iowa city, Iowa, USA - Online CME

Familial hypercholesterolemia: Diagnosis and management

10' education - Apr. 10, 2018 - Prof. Frederick Raal - Johannesburg, South Africa

PCSK9 inhibition across a wide spectrum of patients: One size fits all?

10' education - Aug. 26, 2017 - Barcelona, Spain - G. Kees Hovingh, MD, AMC, Amsterdam, The Netherlands - PACE-CME symposium at ESC 2017 - Online CME

Understanding new PCSK9 outcome data: From the LDL-C hypothesis to LDL-c causality

10' education - Aug. 26, 2017 - ESC 2017, Barcelona, Spain - John Chapman, PhD, Paris, France - PACE-CME symposium - Online CME

CV outcomes with a PCSK9 inhibitor: FOURIER study

3' education - Mar. 16, 2017

A minority of FH patients is identified and labeled as such, which impacts treatment

10' education - Aug. 29, 2016 - ESC Rome, Italy - Prof. Kausik Ray, MD (London, UK)
##FULL_TITLE##

Frequency apheresis lowered in FH patient receiving PCSK9-inhibiting treatment

3' education - Oct. 4, 2016 - ESC - 2016 Rome - Prof Patrick M Moriarty, MD (University of Kansas Medical Center, KS, USA)

Preparing for a novel era in CV prevention: Where do PCSK9 inhibitors fit in lipid management?

10' education - Aug. 27, 2016 - ESC 2016, Rome - John Kastelein, MD – Academic Medical Center, Amsterdam, The Netherlands
##FULL_TITLE##

Impacting lipid disorders through personalised healthcare

3' education - Feb. 2, 2016 - VBWG, Orlando - Daniel J. Rader, M.D.
##FULL_TITLE##

Accumulating clinical data on PCSK9 inhibition: What are the key lessons?

10' education - Sep. 30, 2015 - ESC 2015 London - Paul M Ridker, MD – Brigham and Women’s Hospital, Harvard Medical School, Boston, USA
##FULL_TITLE##

Lipid Management 2020: A glance at the future

10' education - Sep. 24, 2015
##FULL_TITLE##

A new prediction tool to identify disease-causing mutations in familial hypercholesterolaemia

3' education - May 24, 2015 - ISA2015, Amsterdam - Joost Besseling
##FULL_TITLE##

FH: Call for investigators to get involved

3' education - May 23, 2015 - PACE Lipid Masterclass - Amsterdam, May 23 2015 - Prof. Evan Stein
##FULL_TITLE##

Homozygous FH: treatment challenges

3' education - May 23, 2015 - PACE Lipid Masterclass - Amsterdam, May 23 2015 - Prof. Frederick Raal
##FULL_TITLE##

PCSK9-inhibitor less frequently administered may be effective treatment option

3' education - June 15, 2015 - ISA Amsterdam - Prof. Eli Roth
##FULL_TITLE##

TAUSSIG: clinically relevant LDL-lowering in difficult to treat patients

3' education - June 15, 2015 - ISA2015, Amsterdam - Prof. Frederick Raal
##FULL_TITLE##

Screening for Familial Hypercholesterolaemia

3' education - May 23, 2015 - PACE Lipid Masterclass - Amsterdam, May 23 2015 - dr. Kees Hovingh
##FULL_TITLE##

Strong reduction CV events in FH patients with ApoB-inhibitor

3' education - May 24, 2015 - ISA Amsterdam, May 24, 2015 - Dr. Paul Barton Duell
##FULL_TITLE##

Unique Dutch collaborative effort to identify FH patients

3' education - Apr. 1, 2015 - Amersfoort, The Netherlands - Dr. Janneke Wittekoek
##FULL_TITLE##

OSLER studies Compelling data on PCSK9 inhibition

3' education - Mar. 15, 2015 - ACC 2015, San Diego - Marc Sabatine, MD Boston
##FULL_TITLE##

OSLER 1 & 2: Long term efficacy and safety outcomes PCSK9 inhibition

3' education - Mar. 16, 2015 - ACC 2015, San Diego - Prof.dr. John Kastelein
##FULL_TITLE##

2014: the major lipid developments in review

3' education - Dec. 20, 2014 - Amsterdam - Prof. John JP Kastelein
##FULL_TITLE##

FH in Europe: Need for a registry

3' education - Nov. 10, 2014 - Zeist, The Netherlands - dr Kees Hovingh & Eric Bruckert
##FULL_TITLE##

First European experience with human MTP-inhibitor in HoFH

10' education - Oct. 24, 2014
##FULL_TITLE##

PCSK9 inhibition: Clinical Update 2014

3' education - Oct. 29, 2014 - Snapshot 2014 - Dr Evan Stein
##FULL_TITLE##

HoFH: New insights in prevalence and therapy

3' education - Oct. 26, 2014 - Snapshot 2014 - dr Kees Hovingh
##FULL_TITLE##

HoFH: New insights and expanding therapeutic options

10' education - Sep. 6, 2014 - Snapshot 2014 - Dr. Kees Hovingh, AMC, Amsterdam, The Netherlands
##FULL_TITLE##

PCSK9 inhibition: Novel insights into a new therapeutic approach for the lowering of LDL-C: the PCSK9 saga

10' education - Sep. 3, 2014
##FULL_TITLE##

Biology and validation of PCSK9 as a novel target to lower LDL-C

10' education - Aug. 30, 2014 - Barcelona, ESC - Prof. John JP Kastelein
##FULL_TITLE##

LDL cholesterol, LDL receptor & PCSK9

3' education - July 31, 2013
##FULL_TITLE##

Emerging therapies to lower LDL-cholesterol

10' education - May 8, 2014

On demand 10" video

Familial Hypercholesterolemia and Lp(a)

10' education - July 14, 2020 - Nick Nurmohamed, MD

Familial Hypercholesterolemia: Why and how to screen?

10' education - June 30, 2020 - Prof. Kees Hovingh, MD, PhD

Tools to detect FH

10' education - June 23, 2020 - Rens Reeskamp, MD

Familial hypercholesterolemia in children and adolescents

10' education - June 2, 2020 - Bert Wiegman, MD, PhD

Identifying patients for PCSK9 therapy

10' education - Jan. 16, 2019 - Kees Hovingh, MD - Amsterdam, The Netherlands - Online CME

Novel PCSK9 outcomes in perspective: Lessons from FOURIER & ODYSSEY

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - Prof. Jennifer Robinson, MD - Iowa city, Iowa, USA - Online CME

Familial hypercholesterolemia: Diagnosis and management

10' education - Apr. 10, 2018 - Prof. Frederick Raal - Johannesburg, South Africa

PCSK9 inhibition across a wide spectrum of patients: One size fits all?

10' education - Aug. 26, 2017 - Barcelona, Spain - G. Kees Hovingh, MD, AMC, Amsterdam, The Netherlands - PACE-CME symposium at ESC 2017 - Online CME

Understanding new PCSK9 outcome data: From the LDL-C hypothesis to LDL-c causality

10' education - Aug. 26, 2017 - ESC 2017, Barcelona, Spain - John Chapman, PhD, Paris, France - PACE-CME symposium - Online CME

A minority of FH patients is identified and labeled as such, which impacts treatment

10' education - Aug. 29, 2016 - ESC Rome, Italy - Prof. Kausik Ray, MD (London, UK)

Preparing for a novel era in CV prevention: Where do PCSK9 inhibitors fit in lipid management?

10' education - Aug. 27, 2016 - ESC 2016, Rome - John Kastelein, MD – Academic Medical Center, Amsterdam, The Netherlands
##FULL_TITLE##

Accumulating clinical data on PCSK9 inhibition: What are the key lessons?

10' education - Sep. 30, 2015 - ESC 2015 London - Paul M Ridker, MD – Brigham and Women’s Hospital, Harvard Medical School, Boston, USA
##FULL_TITLE##

Lipid Management 2020: A glance at the future

10' education - Sep. 24, 2015
##FULL_TITLE##

First European experience with human MTP-inhibitor in HoFH

10' education - Oct. 24, 2014
##FULL_TITLE##

HoFH: New insights and expanding therapeutic options

10' education - Sep. 6, 2014 - Snapshot 2014 - Dr. Kees Hovingh, AMC, Amsterdam, The Netherlands
##FULL_TITLE##

PCSK9 inhibition: Novel insights into a new therapeutic approach for the lowering of LDL-C: the PCSK9 saga

10' education - Sep. 3, 2014
##FULL_TITLE##

Biology and validation of PCSK9 as a novel target to lower LDL-C

10' education - Aug. 30, 2014 - Barcelona, ESC - Prof. John JP Kastelein
##FULL_TITLE##

Emerging therapies to lower LDL-cholesterol

10' education - May 8, 2014

Statin therapy during pregnancy?

5' education - June 9, 2021 - Prof. Maciej Banach, PhD, MD
Is it time to reconsider the recommendations on lipid-lowering therapy in pregnant women? In order to answer this question, prof. Banach provides an overview of studies on this topic.

Is it time to reconsider the recommendations on lipid-lowering therapy in pregnant women? In order to answer this question, prof. Banach provides an overview of studies on this topic.

Huge advantage with ANGPTL3 inhibitor for HoFH patients with minimal to zero LDLR activity

3' education - Oct. 6, 2020 - Prof. Frederick Raal, MD
A post-hoc analysis of the ELIPSE HoFH trial in patients with little to no LDL receptor activity demonstrated a large reduction of LDL-c with the ANGPTL3 inhibitor evinacumab compared to placebo.

EAS 2020 A post-hoc analysis of the ELIPSE HoFH trial in patients with little to no LDL receptor activity demonstrated a large reduction of LDL-c with the ANGPTL3 inhibitor evinacumab compared to placebo.

A novel small binding protein that targets PCSK9

3' education - Oct. 6, 2020 - Prof. Evan Stein, MD, PhD
Prof. Stein gives an overview of studies with the small binding protein targeting PCSK9, named LIB003.

EAS 2020 Prof. Stein gives an overview of studies with the small binding protein targeting PCSK9, named LIB003.

Small interfering RNA against PCSK9 reduces LDL-c in HeFH independent of genotype

3' education - Oct. 6, 2020 - Prof. Frederick Raal, MD
A subanalysis of the ORION-9 trial demonstrated that across subgroups of genotypes for HeFH, inclisiran (a small interfering RNA against PCKS9) was equally effective in reducing LDL-c.

EAS 2020 A subanalysis of the ORION-9 trial demonstrated that across subgroups of genotypes for heterozygous FH, inclisiran was equally effective in reducing LDL-c.

Familial Hypercholesterolemia and Lp(a)

10' education - July 14, 2020 - Nick Nurmohamed, MD
Nick Nurmohamed explains what Lp(a) is and how correction of LDL-c for Lp(a) reduces genetic testing for FH.

Nick Nurmohamed explains what Lp(a) is and how correction of LDL-c for Lp(a) reduces genetic testing for FH.

Familial Hypercholesterolemia: Why and how to screen?

10' education - June 30, 2020 - Prof. Kees Hovingh, MD, PhD
In this video internist Kees Hovingh discusses why screening for FH is important and tools used for its diagnosis.

In this video, internist Kees Hovingh discusses why screening for FH is important and how to identify individual FH patients and their families. With question to test your knowledge.

Tools to detect FH

10' education - June 23, 2020 - Rens Reeskamp, MD
Rens Reeskamp discusses diagnostic tools of FH that may increase the chance of finding patients with an FH-causing mutation.

Rens Reeskamp discusses tools that may help to increase the chance of finding FH patients. With question to test your knowledge.

Familial hypercholesterolemia in children and adolescents

10' education - June 2, 2020 - Bert Wiegman, MD, PhD
Pediatric cardiologist Bert Wiegman discusses the need for early detection and treatment of children with familial hypercholesterolemia

Pediatric cardiologist Bert Wiegman discusses the need for early detection and treatment of children with familial hypercholesterolemia. With question to test your knowledge.

One step closer to controlling LDL-c levels in HoFH with PCSK9i

3' education - Apr. 9, 2020 - Dirk Blom, PhD
Dirk Blom discusses the design and outcomes in the ODYSSEY HoFH trial, evaluating LDL-c lowering and safety of alirocumab in HoFH patients.

ACC 2020 Dirk Blom discusses the design and outcomes of the ODYSSEY HoFH trial, evaluating LDL-c lowering and safety of alirocumab in HoFH patients.

Remarkable reduction of LDL-c with antibody against angiopoietin-like protein 3 in HoFH

3' education - Apr. 1, 2020 - Prof. Frederick Raal, PhD - ACC 2020
An antibody against angiopoietin-like protein 3 (ANGPTL3) resulted in lowering of LDL-c in homozygous FH patients, independent of LDL receptor function.

ACC 2020 An antibody against angiopoietin-like protein 3 (ANGPTL3) resulted in lowering of LDL-c in homozygous FH patients, independent of LDL receptor function.

The mechanism of action of bempedoic acid

Feb. 2, 2020

Learn how bempedoic acid an ACL inhibtor works in reducing LDL-c

New tool can help identify FH patients

3' education - Nov. 17, 2019 - Willem Bax, Alkmaar - AHA 2019, Philadelphia
A new tool, connected to the electronic patient files corrects for statin use (type and dose) to determine untreated LDL-c levels and the Dutch lipid score.

AHA 2019 A new tool, connected to the electronic patient files corrects for statin use (type and dose) to determine untreated LDL-c levels and the Dutch lipid score.

What are the most important changes in the 2019 ESC/EAS Dyslipidemia Guidelines?

5' education - Oct. 23, 2019 - Paris, France - Prof. François Mach, MD
Cilie van 't Klooster asks prof. Mach to summarize the most important changes in the 2019 ESC/EAS dyslipidemia guidelines.

CSI Paris Cilie van 't Klooster asks prof. Mach to summarize the most important changes in the 2019 ESC/EAS dyslipidemia guidelines.

Prevalence and relevance of elevated Lp(a) in familial hypercholesterolemia

5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Prof. Børge Nordestgaard, MD
The prevalence of clinical FH was investigated in the Copenhagen General Population Study with adjustment for the cholesterol content in Lp(a). Prof. Nordestgaard shares possible ways to interpret these results.

Lp(a) meeting The prevalence of clinical FH was investigated in the Copenhagen General Population Study with adjustment for the cholesterol content in Lp(a). Prof. Nordestgaard shares possible ways to interpret these results.

Efforts to move universal cholesterol screening before the age of 20 forward

3' education - May 29, 2019 - Maastricht, The Netherlands - Professor Kausik Ray, MD
Prof. Kausik Ray talks about the Familial Hypercholesterolemia Studies Collaboration, which was established to address the unmet need to influence global policy change regarding screening for FH patients early in life.

EAS 2019 Prof. Kausik Ray talks about the Familial Hypercholesterolemia Studies Collaboration, which was established to address the unmet need to influence global policy change regarding screening for FH patients early in life.

Challenges for screening and treatment of FH patients in clinical cardiology

Expert Meeting on LDL-c & PCSK9 inhibition in high CV risk patients

5' education - Feb. 13, 2019 - Kausik Ray, Kees Hovingh - Online CME
Identification of FH in ACS patients is crucial, as it has an impact on the clinical trajectory. Prof. Hovingh discusses how to classify these patients and their prognosis.

Identification of FH in ACS patients is crucial, as it has an impact on the clinical trajectory. Prof. Hovingh discusses how to classify these patients and their prognosis.

Identifying patients for PCSK9 therapy

PCSK9: Outcomes and trials in clinical perspective

10' education - Jan. 16, 2019 - Kees Hovingh, MD - Amsterdam, The Netherlands - Online CME
PCSK9 inhibitors should be mainly considered for the highest risk categories on maximally tolerated statin plus ezetimibe. Prof. Kees Hovingh discusses how to identify these high risk patients.

PCSK9: Outcomes and trials in clinical perspective PCSK9 inhibitors should be mainly considered for the highest risk categories on maximally tolerated statin plus ezetimibe. Prof. Kees Hovingh discusses how to identify these high risk patients.

Novel PCSK9 outcomes in perspective: Lessons from FOURIER & ODYSSEY

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - Prof. Jennifer Robinson, MD - Iowa city, Iowa, USA - Online CME
Prof. Jennifer Robinson illustrates the importance of baseline LDL-c levels in CV risk reduction with PCSK9 inhibitors and explains which patients should get this treatment.

Prof. Jennifer Robinson illustrates the importance of baseline LDL-c levels in CV risk reduction with PCSK9 inhibitors and explains which patients should get this treatment.

Familial hypercholesterolemia: Diagnosis and management

10' education - Apr. 10, 2018 - Prof. Frederick Raal - Johannesburg, South Africa
Prof. Frederick Raal describes the prevalence and phenotypic variability of FH. Novel therapies have changed FH from a lethal disorder to a manageable dyslipidaemia.

Prof. Frederick Raal describes the prevalence and phenotypic variability of FH. Novel therapies have changed FH from a lethal disorder to a manageable dyslipidaemia.

PCSK9 inhibition across a wide spectrum of patients: One size fits all?

10' education - Aug. 26, 2017 - Barcelona, Spain - G. Kees Hovingh, MD, AMC, Amsterdam, The Netherlands - PACE-CME symposium at ESC 2017 - Online CME
Lecture by Prof Kees Hovingh held at symposium on PCSK9 inhibition & Cardiovascular Outcomes:  Review of lipid targets and treatment strategies

This lecture was part of a CME accredited symposium: PCSK9 inhibition & Cardiovascular Outcomes: Review of lipid targets and treatment strategies held at ESC 2017 in Barcelona on August 26, 2017

Understanding new PCSK9 outcome data: From the LDL-C hypothesis to LDL-c causality

10' education - Aug. 26, 2017 - ESC 2017, Barcelona, Spain - John Chapman, PhD, Paris, France - PACE-CME symposium - Online CME

This lecture was part of a CME accredited symposium: PCSK9 inhibition & Cardiovascular Outcomes: Review of lipid targets and treatment strategies held at ESC 2017 in Barcelona on August 26, 2017

CV outcomes with a PCSK9 inhibitor: FOURIER study

3' education - Mar. 16, 2017
Marc S. Sabatine (Boston) presented the FOURIER-study, which evaluated a PCSK9 inhibitor during two years in over 27000 high-risk patients. LDL-c was reduced by 59%. Both the primary and the secundary clinical endpoint were significantly reduced.

ACC 2017 Marc S. Sabatine (Boston) presented the FOURIER-study, which evaluated a PCSK9 inhibitor during two years in over 27000 high-risk patients. LDL-c was reduced by 59%. Both the primary and the secundary clinical endpoint were significantly reduced.

A minority of FH patients is identified and labeled as such, which impacts treatment

10' education - Aug. 29, 2016 - ESC Rome, Italy - Prof. Kausik Ray, MD (London, UK)
A minority of FH patients is identified and labeled as such, which impacts treatment

CSI Rome Kausik Ray was involved in a project which investigated in UK databases which proportion of the predicted population with FH has been identified and is labelled as such. Johanneke van den Berg and Corien Flint discuss the consequences of underdetection with him, and how this may be improved.

Frequency apheresis lowered in FH patient receiving PCSK9-inhibiting treatment

3' education - Oct. 4, 2016 - ESC - 2016 Rome - Prof Patrick M Moriarty, MD (University of Kansas Medical Center, KS, USA)
##KEY_PHRASE##

Patrick Moriarty shares the results of the ODYSSEY-ESCAPE trial, set up to evaluate whether treatment with alirocumab could diminish or eradicate the need for lipoprotein apheresis FH patients with severely elevated LDL-c.

Preparing for a novel era in CV prevention: Where do PCSK9 inhibitors fit in lipid management?

10' education - Aug. 27, 2016 - ESC 2016, Rome - John Kastelein, MD – Academic Medical Center, Amsterdam, The Netherlands

John Kastelein, MD (Amsterdam, The Netherlands) indicates the position of PCSK9-inhibitors in current lipid management, especially in patients with FH.

Impacting lipid disorders through personalised healthcare

3' education - Feb. 2, 2016 - VBWG, Orlando - Daniel J. Rader, M.D.
##KEY_PHRASE##

Daniel Rader (Philadelphia, PA, USA) looks forward to a future of personalised medicine in FH, which should benefit from specific biomarkers and novel medications, to better treat this common lipid disorder. But first, FH patients need to be better identified.

Accumulating clinical data on PCSK9 inhibition: What are the key lessons?

Paul M Ridker, MD Harvard Medical School, Boston, USA

10' education - Sep. 30, 2015 - ESC 2015 London - Paul M Ridker, MD – Brigham and Women’s Hospital, Harvard Medical School, Boston, USA
##KEY_PHRASE##

Prof Paul Ridker describes the remarkable history of the lipid hypothesis and the potential role of PCSK9 inhibition

Lipid Management 2020: A glance at the future

Kausik Ray, Imperial College London, UK

10' education - Sep. 24, 2015
##KEY_PHRASE##

Prof Kausik Ray provides his view on upcoming changes in lipid management and potential solutions to address new challenges

A new prediction tool to identify disease-causing mutations in familial hypercholesterolaemia

3' education - May 24, 2015 - ISA2015, Amsterdam - Joost Besseling
##KEY_PHRASE##

ISA 2015 Joost Besseling and colleagues developed a new prediction model to determine which patients might have a disease-causing FH mutation. The model works particularly well in young patients with familial hypercholesterolaemia.

FH: Call for investigators to get involved

3' education - May 23, 2015 - PACE Lipid Masterclass - Amsterdam, May 23 2015 - Prof. Evan Stein
##KEY_PHRASE##

Lipid MC 2015 Prof Evan Stein explains why it is important that more international physicians become actively involved in FH research, and he invites those interested to become an FH investigator, which will benefit both patients and the investigator.

Homozygous FH: treatment challenges

3' education - May 23, 2015 - PACE Lipid Masterclass - Amsterdam, May 23 2015 - Prof. Frederick Raal
##KEY_PHRASE##

Lipid MC 2015 Prof. Frederick Raal considers the challenges to adequately lower LDL-c levels in patients with HoFH, and how they may be overcome in the near future.

PCSK9-inhibitor less frequently administered may be effective treatment option

3' education - June 15, 2015 - ISA Amsterdam - Prof. Eli Roth
##KEY_PHRASE##

ISA2015 | Clinical Breakthroughs The ODYSSEY CHOICE I evaluated the efficacy of PCSK9-inhibitor alirocumab given once every four weeks instead of every two weeks. Prof. Eli Roth considers this dosing scheme a good option for patients who prefer monthly injections.

TAUSSIG: clinically relevant LDL-lowering in difficult to treat patients

3' education - June 15, 2015 - ISA2015, Amsterdam - Prof. Frederick Raal
##KEY_PHRASE##

ISA2015 | Clinical Breakthroughs Based on the TAUSSIG study, a longer term study of treatment with PCSK9 inhibitor evolocumab in a relatively large group of patients with homozygous FH, prof. Frederick Raal concludes that we now have an additional therapy for these difficult to treat patients.

Screening for Familial Hypercholesterolaemia

3' education - May 23, 2015 - PACE Lipid Masterclass - Amsterdam, May 23 2015 - dr. Kees Hovingh
##KEY_PHRASE##

Lipid MC 2015 Dr. Kees Hovingh discusses recent insights into the actual prevalence of homozygous and heterozygous FH, how FH patients can best be identified, and how they should be managed.

Strong reduction CV events in FH patients with ApoB-inhibitor

3' education - May 24, 2015 - ISA Amsterdam, May 24, 2015 - Dr. Paul Barton Duell
##KEY_PHRASE##

ISA 2015 In a Clinical Breakthrough Session, dr. Paul Barton Duell (endocrinologist, Portland, USA) presented a striking reduction of MACE with treatment with the antisense oligonucleotide against apoB mRNA mipomersen in a very high risk population.

Unique Dutch collaborative effort to identify FH patients

3' education - Apr. 1, 2015 - Amersfoort, The Netherlands - Dr. Janneke Wittekoek
##KEY_PHRASE##

Dr. Janneke Wittekoek (director LEEFH Foundation) explains how a unique collaborative effort, paid for by reimbursements from insurance companies, sets out to find all patients with familial hypercholesterolaemia in The Netherlands.

OSLER studies Compelling data on PCSK9 inhibition

3' education - Mar. 15, 2015 - ACC 2015, San Diego - Marc Sabatine, MD Boston
##KEY_PHRASE##

Dr. Marc S Sabatine MD, Boston, describes the very compelling results of OSLER studies and the potential for PCSK9 inhibition to reduce major cardiovascular events through robust LDL-c reduction.

OSLER 1 & 2: Long term efficacy and safety outcomes PCSK9 inhibition

3' education - Mar. 16, 2015 - ACC 2015, San Diego - Prof.dr. John Kastelein
##KEY_PHRASE##

ACC 2015 Prof. John Kastelein, Amsterdam, comments on the results of the OSLER program with PCSK9 inhibitor evolocumab and provides a perspective on the potential of PCSK9 inhibitors.

2014: the major lipid developments in review

3' education - Dec. 20, 2014 - Amsterdam - Prof. John JP Kastelein
##KEY_PHRASE##

Prof. John Kastelein, Amsterdam, (PACE director) reviews the major news on the 3 lipoproteins: LDL-c, HDL-c and TG that provide new understanding and implications for the fight against atherosclerosis

FH in Europe: Need for a registry

3' education - Nov. 10, 2014 - Zeist, The Netherlands - dr Kees Hovingh & Eric Bruckert
##KEY_PHRASE##

Drs Eric Bruckert and Kees Hovingh discuss the need for a European database on patients with HoFH and HeFH to better understand the disease and measure efficacy and safety of new medications

First European experience with human MTP-inhibitor in HoFH

Dr. Jeanine Roeters van Lennep

10' education - Oct. 24, 2014
##KEY_PHRASE##

Jeanine Roeters van Lennep, MD PhD (Erasmus MC, Rotterdam, The Netherlands) discusses management of homozygous familial hypercholesterolaemia (HoFH).

PCSK9 inhibition: Clinical Update 2014

3' education - Oct. 29, 2014 - Snapshot 2014 - Dr Evan Stein
##KEY_PHRASE##

Dr. Evan Stein, Cincinnati, USA, with an overview of phase III data with the PCSK9 inhibitor evolocumab as were presented in 2014

HoFH: New insights in prevalence and therapy

3' education - Oct. 26, 2014 - Snapshot 2014 - dr Kees Hovingh
##KEY_PHRASE##

Dr. Kees Hovingh, Amsterdam, NL, shares some new insights in the prevalence of Familial Hypercholesterolemia and novel therapeutic options to lower LDL-c in this patient population

HoFH: New insights and expanding therapeutic options

Dr Kees Hovingh, MD, Amsterdam, The Netherlands

10' education - Sep. 6, 2014 - Snapshot 2014 - Dr. Kees Hovingh, AMC, Amsterdam, The Netherlands
##KEY_PHRASE##

Lecture held by Dr. Kees Hovingh, MD, AMC, Amsterdam, The Netherlands held during the PACE 2014 Snapshot session Novel interventions in cardiovascular disease: Controversies & hot issues in Barcelona.

PCSK9 inhibition: Novel insights into a new therapeutic approach for the lowering of LDL-C: the PCSK9 saga

10' education - Sep. 3, 2014
##KEY_PHRASE##

Lecture by Prof. Evan Stein, Cincinnati, OH, USA held during EBAC accredited symposium 'Innovations in lipid management: Evolving insights and implications from PCSK9 research' held during ESC2014 in Barcelona

Biology and validation of PCSK9 as a novel target to lower LDL-C

Prof. John JP Kastelein

10' education - Aug. 30, 2014 - Barcelona, ESC - Prof. John JP Kastelein
##KEY_PHRASE##

Lecture by Prof. John Kastelein, Amsterdam, The Netherlands, held during EBAC accredited symposium 'Managing Innovations in lipid management: Evolving insights and implications from PCSK9 research' held during ESC2014 in Barcelona

LDL cholesterol, LDL receptor & PCSK9

3' education - July 31, 2013
##KEY_PHRASE##

A mechanism of action animation on the potential role of the inhibition of PCSK9 with a monoclonal antibody

Emerging therapies to lower LDL-cholesterol

Prof. Erik Stroes, MD

10' education - May 8, 2014
##KEY_PHRASE##

Prof. Erik Stroes describes new treatments to lower LDL-cholesterol: PCSK9-inhibitors, ApoB antisense and MTP-inhibitors, discussing several studies presented recently at the ACC-congress.